CHORD THERAPEUTICS
Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. The company is advancing its lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG). The company was founded in 2014 and based in Geneva, Switzerland.
CHORD THERAPEUTICS
Industry:
Biotechnology Pharmaceutical
Founded:
2014-01-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.chordtherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
16 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS AWS Global Accelerator Webflow
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Omega Funds
Omega Funds investment in Series A - Chord Therapeutics
Eclosion SA
Eclosion SA investment in Seed Round - Chord Therapeutics
Official Site Inspections
http://www.chordtherapeutics.com
Unable to get host informations!!!
More informations about "Chord Therapeutics"
Chord Therapeutics - Crunchbase Company Profile & Funding
Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. The company is advancing its lead drug …See details»
Acquisition-of-Chord-Therapeutics - News | Merck
Dec 20, 2021 About Chord Therapeutics Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely …See details»
Chord Therapeutics Company Profile 2024: Valuation, Investors ...
Chord Therapeutics General Information Description. Operator of a pharmaceutical company intended to produce drugs to cure rare neurological diseases. The company is dedicated to …See details»
Merck Expands Neuroinflammatory Pipeline with Acquisition of …
About Chord Therapeutics Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling …See details»
Chord Therapeutics - BioAlps
Avenue de Sécheron 15 1202 Geneva, Switzerland T +41 22 545 12 91. c/o BIOPÔLE SA Secteur Esplanade / Bâtiment Serine Route de la Corniche 8 1066 Epalinges, SwitzerlandSee details»
Chord Therapeutics - Overview, News & Competitors - ZoomInfo
Chord Therapeutics contact info: Phone number: +41 794175474 Website: www.chordtherapeutics.com What does Chord Therapeutics do? Chord Therapeutics is a …See details»
Merck acquires Chord Therapeutics - 2021-12-20 - Crunchbase
Dec 20, 2021 Chord Therapeutics Chord Therapeutics is a clinical stage biopharmaceutical company developing drugs for rare diseases. Acquiring Organization: Merck Merck is a …See details»
Merck acquires Geneva-based biopharmaceutical company Chord …
Nov 8, 2024 Merck invests into Cadribine to try to cure rare neuroinflammatory diseases . Chord Therapeutics (Chord), a clinical-stage biopharmaceutical company developing drugs for rare …See details»
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory …
GENEVA, Dec. 20, 2021 /PRNewswire/ -- Chord Therapeutics (Chord), a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, today …See details»
Merck KGaA buys neuroinflammation firm | C&EN …
Jan 3, 2022 Merck KGaA has acquired the Swiss start-up Chord Therapeutics for an undisclosed sum. Chord launched in 2020 with $16 million in funding to develop cladribine for the treatment of two rare neuroinflammatory diseases. …See details»
CHORD Therapeutics Sàrl - startup.ch
CHORD Therapeutics Sàrl: CHORD Therapeutics is dedicated to repurposing the small molecule drug CRD1, under orphan drug/orphan medicinal product designation, to bring a new effective …See details»
Chord Therapeutics Company Profile - Office Locations ... - Craft
Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. The company aims to develop the first …See details»
Chord Therapeutics - VentureRadar
CHORD Therapeutics is dedicated to repurposing the small molecule drug CRD1, under orphan drug/orphan medicinal product designation, to bring a new effective therapy to patients with life …See details»
Merck Expands Neuroinflammatory Pipeline with Acquisition of …
Dec 21, 2021 About Chord Therapeutics Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely …See details»
Merck KGaA Buys Chord and Its Oral Cladribine Product for NMOSD
Dec 23, 2021 Chord Therapeutics was launched in October 2020 by healthcare venture capital firm Omega Funds. “I am very pleased with Chord’s progress over the last year since our …See details»
Merck acquires Chord Therapeutics to expand neuroinflammatory …
Dec 21, 2021 Merck has acquired Chord Therapeutics to expand its neurology pipeline and develop Chord's lead drug candidate, CRD1 (cladribine), for the treatment of generalized …See details»
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory …
Geneva, December 20, 2021: Chord Therapeutics (Chord), a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, today announces that it is …See details»
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory …
Dec 21, 2021 Chord Therapeutics was launched in October 2020 by leading healthcare venture capital firm Omega Funds, the sole investor in the Company’s USD 16 million Series A …See details»
Chord Therapeutics launches with USD 16 million Series A financing
GENEVA, Switzerland, Oct. 13, 2020 /PRNewswire/ -- Chord Therapeutics, a clinical stage biopharmaceutical company developing drugs for rare diseases, today announces the closing …See details»
Chord gets $16m to challenge Alexion with oral NMOSD drug
Nov 1, 2024 Swiss biotech Chord Therapeutics has come out of stealth mode with a $16 million first-round financing that will be used to progress a repurposed drug for rare disease …See details»